This is a website for healthcare professionals.
90%
of rheumatologists agree AVISE® significantly reduces the time to diagnosis1
Specialty Rheumatology Laboratory
Diagnosing and managing autoimmune rheumatic diseases is complex, you need to have confidence in the quality of your lab results. AVISE® testing is performed exclusively in Exagen’s centralized rheumatology laboratory giving you consistently accurate results. We also have a dedicated physician support team guided by licensed rheumatology advisors.
Unique Algorithm and Biomarkers
AVISE has a proprietary discovery and validation process for accurate and timely detection and disease management. Our two-tier algorithm applies CB-CAPs and other SLE-associated markers to our unique AVISE Lupus Index, turning isolated data points into actionable information for better clinical decisions.2
Accuracy is Our Top Priority
We exceed expectations by combining extensive training and expertise with state-of-the-art technology. Exagen is proud to be the first U.S. clinical lab to complete an in-house validation of digital immunofluorescence.
A Glimpse into Our Advanced Methods
ELISA-ANA
ANA is initially performed by a special ELISA assay that includes HEp-2 extract to improve sensitivity
HEp-2 ANA
All ANA tests are also processed using the gold standard HEp-2 immunofluorescent substrate
Testing Validation
HEp-2 Immunofluorescence Assay (IFA) results are analyzed with digital microscopy before undergoing human review and confirmation
Crithidia IFA
For dsDNA testing, Exagen uses a high-quality ELISA assay and all positive results are confirmed by Crithidia IFA
Real world evidence confirms that AVISE enables decisive clinical action in the differential diagnosis of SLE, superior to standard of care
Cell-bound complement activation products in systemic lupus erythematosus: Comparison with anti-double-stranded DNA and standard complement measurements.
Putterman C, Furie R, Ramsey-Goldman R, et al. Lupus Sci Med. 2014;1(1):1-8.
View full studyCell-bound complement activation products in systemic lupus erythematosus: Comparison with anti-double-stranded DNA and standard complement measurements.
Putterman C, Furie R, Ramsey-Goldman R, et al. Lupus Sci Med. 2014;1(1):1-8.
View full studyThe Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus.
Mossell J, Goldman JA, Barken D, Alexander RV. Open Rheumatol J. 2016;10(1):71-80.
View full studyRandomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE.
Wallace DJ, Alexander RV, O’Malley T, et al. Lupus Sci Med. 2019;6(1):6-11.
View full studyComplement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus.
Ramsey‐Goldman R, Alexander RV, Massarotti EM, et al.
Arthritis Rheumatol. 2020;72(1):78-88.
Connective Tissue Disease test in predicting lupus diagnosis and progression.
Liang E, Taylor M, McMahon M. Utility of the AVISE Lupus Sci Med. 2020;7(1):4-6.
View full studyLoad More
Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using a Multivariate Assay Panel (MAP).
Clarke AE, Weinstein A, Piscitello A, et al. ACR Open Rheumatology. 2020;0(0):1-11.
View full studyA multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus.
Alexander RV, Rey DS, Conklin J, et al.
Lupus Sci Med. 2021;8(1):e000528.
Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus.
O'Malley T, et al. Journal of Managed Care + Specialty Pharmacy 2022.
View full study
Accelerated Time to Diagnosis Leads to Better Patient Care
Diagnosing and managing autoimmune rheumatic diseases is complex, you need to have confidence in the quality of your lab results. AVISE® testing is performed exclusively in Exagen’s centralized rheumatology laboratory giving you consistently accurate results. We also have a dedicated physician support team guided by licensed rheumatology advisors.
-
58 Serial Tests
The average number of general tests a patient endures.3
-
6 Years to Diagnosis
Inadequate diagnostic tools create delays in diagnosis.4
-
Delayed Treatment
Imprecise testing data leads to delayed treatment and results in major organ involvement for most SLE patients.
-
Increased Disease Burden
The data shows that diagnostic delay from the time of symptom onset is significantly associated with increased disease activity, SLE-damage, fatigue, and decreased quality of life.5
Would you like more information? Speak to an AVISE representative.
Contact Representative
References:
- Data on file.
- Clarke et al. Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using a Multivariate Assay Panel (MAP). ACR Open Rheumatology. 2020 Nov;2(11):629-639. doi: 10.1002/acr2.11177. Epub 2020 Oct 12. PMID: 33044050; PMCID: PMC7672303.
- Al Sawah et al. SAT0423 Understanding Delay in Diagnosis, Access to Care and Satisfaction with Care in Lupus: Findings from a Cross-Sectional Online Survey in the United States Annals of the Rheumatic Diseases 2015;74:812.
- Kernder A,et al. Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort. Lupus. 2021 Mar;30(3):431-438. doi: 10.1177/0961203320983445. Epub 2021 Jan 5. PMID: 33402036; PMCID: PMC7933718.